Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Substance (Drug) Abuse - Global Clinical Trials Review, 2024" has been added to ResearchAndMarkets.com's offering.
The clinical trial report provides an overview of Substance (Drug) Abuse Clinical trials scenario. This report provides top line data relating to the clinical trials on Substance (Drug) Abuse.
The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Key Topics Covered:
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Substance (Drug) Abuse Therapeutics Clinical Trials
- Prominent Drugs
- Clinical Trial Profile Snapshots
Company Coverage:
- Pfizer Inc
- Indivior Plc
- GSK plc
- Alkermes Plc
- Johnson & Johnson
- Novo Holdings AS
- US WorldMeds
- ICON Plc
- British American Tobacco Plc
- AstraZeneca Plc
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/swc56b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
